tradingkey.logo
搜尋

PharmaCyte Biotech Inc

PMCB
添加自選
0.584USD
-0.016-2.67%
收盤 07-31 16:00美東報價延遲15分鐘
6.27M總市值
虧損本益比TTM

關於 PharmaCyte Biotech Inc 公司

PharmaCyte Biotech, Inc. is a biotechnology company, which is focused on developing cellular therapies for cancer based upon a proprietary cellulose-based live cell encapsulation technology known as Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including locally advanced, inoperable pancreatic cancer (LAPC) will be developed. The Cell-in-a-Box encapsulation technology potentially enables genetically engineered live human cells to be used as a means to produce various biologically active molecules. The technology is intended to result in the formation of pinhead-sized cellulose-based porous capsules in which genetically modified live human cells can be encapsulated and maintained. In a laboratory setting, this proprietary live cell encapsulation technology has been shown to create a micro-environment in which encapsulated cells survive and flourish.

PharmaCyte Biotech Inc簡介

公司代碼PMCB
公司名稱PharmaCyte Biotech Inc
上市日期Sep 11, 2003
CEOSilverman (Joshua N)
員工數量2
證券類型Ordinary Share
年結日Sep 11
公司地址3960 Howard Hughes Parkway, Suite 500
城市LAS VEGAS
上市交易所NASDAQ OMX - NASDAQ BASIC
國家United States of America
郵編89169
電話19175952850
網址https://pharmacyte.com/
公司代碼PMCB
上市日期Sep 11, 2003
CEOSilverman (Joshua N)

PharmaCyte Biotech Inc公司高管

名稱
名稱/職務
職務
持股
持股變動
Mr. Jonathan L. Schechter
Mr. Jonathan L. Schechter
Independent Director
Independent Director
132.50K
-45.28%
Mr. Robert Weinstein
Mr. Robert Weinstein
Independent Director
Independent Director
41.25K
--
Mr. Carlos A. Trujillo, CPA
Mr. Carlos A. Trujillo, CPA
Chief Financial Officer
Chief Financial Officer
10.40K
--
Dr. Michael M. Abecassis, M.D.
Dr. Michael M. Abecassis, M.D.
Independent Director
Independent Director
--
--
Mr. Joshua N. (Josh) Silverman
Mr. Joshua N. (Josh) Silverman
Interim Chairman of the Board, Interim Chief Executive Officer and Interim President
Interim Chairman of the Board, Interim Chief Executive Officer and Interim President
--
--
Mr. Wayne R. Walker
Mr. Wayne R. Walker
Independent Director
Independent Director
--
--
名稱
名稱/職務
職務
持股
持股變動
Mr. Jonathan L. Schechter
Mr. Jonathan L. Schechter
Independent Director
Independent Director
132.50K
-45.28%
Mr. Robert Weinstein
Mr. Robert Weinstein
Independent Director
Independent Director
41.25K
--
Mr. Carlos A. Trujillo, CPA
Mr. Carlos A. Trujillo, CPA
Chief Financial Officer
Chief Financial Officer
10.40K
--
Dr. Michael M. Abecassis, M.D.
Dr. Michael M. Abecassis, M.D.
Independent Director
Independent Director
--
--
Mr. Joshua N. (Josh) Silverman
Mr. Joshua N. (Josh) Silverman
Interim Chairman of the Board, Interim Chief Executive Officer and Interim President
Interim Chairman of the Board, Interim Chief Executive Officer and Interim President
--
--
Mr. Wayne R. Walker
Mr. Wayne R. Walker
Independent Director
Independent Director
--
--

常見問題

PharmaCyte Biotech Inc的前五大股東是誰?

PharmaCyte Biotech Inc的前五大股東如下:Mr. Jonathan L. Schechter

有多少機構持有PharmaCyte Biotech Inc(PMCB)的股份?

截至2026Q1,共有67家機構持有PharmaCyte Biotech Inc的股份,合計持有的股份價值約為1.07M,占公司總股份的9.99% 。與2025Q4相比,機構持股有所增加,增幅為347985.00。
tradingkey.logo
風險提示:我們的網站和行動應用程式僅提供關於某些投資產品的一般資訊。Finsights 不提供財務建議或對任何投資產品的推薦,且提供此類資訊不應被解釋為 Finsights 提供財務建議或推薦。
投資產品存在重大投資風險,包括可能損失投資的本金,且可能並不適合所有人。投資產品的過去表現並不代表其未來表現。
Finsights 可能允許第三方廣告商或關聯公司在我們的網站或行動應用程式的任何部分放置或投放廣告,並可能根據您與廣告的互動情況獲得報酬。
© 版權所有: FINSIGHTS MEDIA PTE. LTD. 版權所有